The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Updates from the Phase III SEQUOIA trial: zanubrutinib vs. BR in the treatment of patients with CLL
In this video, Peter Hillmen, MBChB, FRCP, FRCPath, PhD, University of Leeds, Leeds, UK, discusses some results from the Phase III SEQUOIA (BGB-3111-304; NCT03336333) trial, which compared the use of zanubrutinib versus bendamustine and rituximab (BR) therapy in patients with CLL. Dr Hillmen reports on the results of this trial, including the significant improvement observed with the use of zanubrutinib, especially in the IGHV unmutated patient subset. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
